Early study finds anacetrapib safe and effective

 Anacetrapib, Merck’s CETP inhibitor, was safe and effective in a study of 589 patients. The results are in sharp contrast to those for torcetrapib, the Pfizer CETP inhibitor that was pulled from development after it was found to raise blood pressure. In the new study, anacetrapib had no discernible effect on blood pressure.  The full text of the study, from the February issue of the American Heart Journal, is available for free at the AHJ site.

You can read a good discussion of the study, with useful commentary from Roger Blumenthal, Christie Ballantyne, and John Kastelein, in an excellent Heartwire news story by Sue Hughes.

Speak Your Mind